e-learning
resources
Berlin 2001
Sunday 23.09.2001
Inflammation, infection and exercise capacity in cystic fibrosis patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Revisiting FEV1 in cystic fibrosis
P. Camargos, I. Assis, F. Reis, N. Sulmonett, A. Carneiro (Belo Horizonte, Brazil)
Source:
Annual Congress 2001 - Inflammation, infection and exercise capacity in cystic fibrosis patients
Session:
Inflammation, infection and exercise capacity in cystic fibrosis patients
Session type:
Thematic Poster Session
Number:
862
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Camargos, I. Assis, F. Reis, N. Sulmonett, A. Carneiro (Belo Horizonte, Brazil). Revisiting FEV1 in cystic fibrosis. Eur Respir J 2001; 16: Suppl. 31, 862
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Exercise capacity in patients with cystic fibrosis vs non-cystic fibrosis bronchiectasis
Source: International Congress 2018 – Mechanisms that underlie exercise limitation in various respiratory diseases
Year: 2018
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Source: Eur Respir J 2012; 40: 61-66
Year: 2012
Cystic fibrosis fibrosis bronchiectasis
Source: Virtual Congress 2020 – Paediatric year in review
Year: 2020
Neomacrolides in cystic fibrosis
Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease
Year: 2012
Dynamic hyperinflation in cystic fibrosis
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012
Longitudinal decline in FEV1 in an adult non-cystic fibrosis bronchiectasis cohort
Source: Eur Respir J 2007; 30: Suppl. 51, 529s
Year: 2007
Diagnosing bronchiectasis and cystic fibrosis
Source: International Congress 2018 – ME8 Diagnosing bronchiectasis and cystic fibrosis
Year: 2018
Lung clearance index predicts pulmonary exacerbations in cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Airway clearance techniques in cystic fibrosis
Source: Eur Respir J 2006; 27: 1082-1083
Year: 2006
Airway inflammation in cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 14-31
Year: 2014
Exercise in cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 203-218
Year: 2014
Improving airway clearance in cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 169-187
Year: 2014
Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2007; 30: Suppl. 51, 528s
Year: 2007
Global impact of bronchiectasis and cystic fibrosis
Source: Breathe 2016; 12: 222-235
Year: 2016
Relationship between airflow limitation and lung volume in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 301s
Year: 2002
Exercise improvements in ivacaftor treated G551D cystic fibrosis patients are not solely related to FEV1 and sweat changes
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Non-cystic fibrosis bronchiectasis
Source: International Congress 2019 – Recent clinical advances in inhalation therapy
Year: 2019
Non-cystic fibrosis bronchiectasis
Source: Virtual Congress 2020 – Paediatric year in review
Year: 2020
Non-cystic fibrosis bronchiectasis
Source: Eur Respir Monogr 2017; 77: 38-57
Year: 2017
Immuno-allertypes in non-cystic fibrosis bronchiectasis
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept